Distribution and case-fatality ratios by cell-type for ovarian carcinomas: A 22-year series of 562 patients with uniform current histological classification

Seidman, Jeffrey D.; Vang, Russell; Ronnett, Brigitte M.; Yemelyanova, Anna; Cosin, Jonathan A.

doi:10.1016/j.ygyno.2014.12.018

Cited by 24 publications

(20 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is in accordance with the distribution obtained in previous studies [23, 24]. Moreover, although LGSC is known to be less sensitive to conventional platinum-based chemotherapy compared to high-grade serous ovarian cancers (HGSC) in the literature, no exact data have been reported [10, 11, 25].…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)

Feng

Wen

et al. 2017

J Ovarian Res

View full text Add to dashboard Cite

BackgroundThe aim of our study was to investigate the clinical features and expression levels of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).MethodsWe retrospectively investigated the clinical features of 26 consecutive patients with LGSC who underwent primary staging or debulking surgery between April 2005 and June 2013 in our center; concomitant primary high-grade serous ovarian cancer (HGSC) patients were randomly selected at a 2:1 ratio for comparison. Tissue microarrays were constructed from the LGSC and HGSC specimens, and the expression levels of six hormone receptors in the hypothalamic pituitary-gonadal axis were analyzed by immunohistochemistry.ResultsThe median (range) age of patients with LGSC was 54 (27–77) years. According to the FIGO staging system, the cases were distributed as follows: stage I, 6 (23.1%); stage II, 0 (0%); stage III, 19 (73.1%); and stage IV, 1 (3.8%). The 2-year and 5-year overall survival rates for LGSC were 91.8% and 67.5%, respectively. The expression levels of the hormone receptors were as follows: ER, 80.8%; PR, 34.6%; AR, 53.8%; FSHR, 84.0%; LHR, 65.4%; and GnRHR, 100%. Hormone receptor-positive patients had a better prognosis compared with hormone receptor-negative patients, but the difference was not significant.ConclusionsOur study presented a higher overall survival rate and distinctive hormone receptor expression levels of LGSC patients compared with the HGSC cohort. Patients with positive hormone receptor expression tended to have a better prognosis than the corresponding hormone receptor negative patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s13048-016-0300-5) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 91%

“…The 5-year overall survival rate of LGSC ranges from 61 to 71% in the literature [6, 23, 24, 26]; the 5-year OS observed in our cohort was 67.5%. Similar to previous studies, we confirmed a higher overall survival rate in LGSC compared with HGSC, although this only approached significance [6, 23, 26–28].…”

Section: Discussionmentioning

confidence: 55%

Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)

Feng

Wen

et al. 2017

J Ovarian Res

View full text Add to dashboard Cite

show abstract

“…Low-grade serous carcinoma is a rare tumor of the ovary that constitutes approximately 5% of all ovarian carcinomas. 3,4 Because of the association between LGOSC and mutations in the regulator components of the mitogen-activated protein kinase pathway ( K-RAS / BRAF mutations), there is a close connection between LGOSC and serous borderline tumors as opposed to the high-grade type. 5 Despite the fact that LGOSC may be closely associated with ovarian low malign potential tumors and a slow growth pattern underlying the histopathologic and molecular characteristics of tumor development, the clinical behavior of LGOSC has some contrasting clinical features such as chemoresistance and high risk of advanced disease stage.…”

Section: Introductionmentioning

confidence: 99%

Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma

Cömert

Türkmen

Mesci

et al. 2019

Tumori

View full text Add to dashboard Cite

Objective: To evaluate the factors predicting oncologic outcomes in low-grade ovarian serous carcinoma (LGOSC). Methods: Seventy patients with LGOSC were included in the study. According to the residual disease present at the end of the initial cytoreductive surgery (CRS), surgical outcomes are defined as follows: maximal CRS for absence of macroscopic residual tumors, optimal CRS for macroscopic residual tumors with diameters ranging from 0.1 to ⩽1 cm diameter, and suboptimal CRS for macroscopic residual tumors measuring >1 cm in diameter. Results: Five-year disease-free survival (DFS) and cancer-specific survival (CSS) were 61% and 83%, respectively. Surgical outcomes were suboptimal in 3 (4.3%) patients, optimal in 8 (11.4%) patients, and maximal in 59 (84.3%) patients. Stage and surgical outcomes were related to DFS ( p < 0.05). Compared with maximal CRS, the presence of residual tumors (suboptimal and optimal debulking) was related to threefold increased risk of disease failure (recurrence or progression) (hazard ratio [95% confidence interval] 3.00 [1.27–7.09]; P=0.012). CSS was associated with disease stage alone ( P=0.03). Advanced stage was related with lower DFS and CSS. Conclusions: Maximal CRS facilitates an improvement in DFS. Achieving no residual disease after the completion of surgery should be a cornerstone of LGOSC management.

show abstract

“…In industrialized countries, including the USA, Japan and UK, ovarian carcinoma is one of the most common gynecological malignancies diseases and the leading cause of gynecological cancer mortality (1,2). There are multiple reasons for this, one cause may be that ovarian carcinoma is generally detected late, almost 70% of all patients present with advanced stage III and IV cancer, and a number of patients are misdiagnosed (3)(4)(5).…”

Section: Introductionmentioning

confidence: 99%

Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma

et al. 2016

View full text Add to dashboard Cite

Abstract. SAM-and SH3-domain containing 1 (SASH1) is a recently identified tumor suppressor gene that is required in the tumorigenesis of breast and other solid carcinomas. The SASH1 protein contains SH3 and SAM domains, indicating that it may serve an important role in intracellular signal transduction. The purpose of the present study was to investigate the expression of SASH1 in ovarian carcinoma and the correlation between its expression with clinical pathological features and clinical significance, and the effect of SASH1 on cell proliferation, apoptosis and migration of ovarian SKOV3 cells. The human ovarian carcinoma tissues and adjacent normal tissues were collected following surgery. Reverse transcription-quantitative polymerase chain reaction and western blot analysis were used to detect the expression levels of SASH1 mRNA and protein, respectively. The expression levels of SASH1 mRNA and protein in ovarian carcinoma tissues were significantly lower than that observed in adjacent normal tissues (P<0.05). The expression levels of SASH1 in samples from patients without lymph nodes metastasis and patients with early FIGO stage was lower than those with lymph nodes metastasis and patients with advanced FIGO stage (P<0.05). Flow cytometry analysis and Transwell invasion chamber experiments were used to investigate the effect of SASH1 on the cell proliferation, apoptosis and migration of SKOV3 cells. The recombinant plasmid pcDNA3.1-SASH1 was constructed and transfected into SKOV3 cells. In addition, the SKOV3 cells in the pcDNA3.1-SASH1 group exhibited significantly reduced cell growth, proliferation, and migration ability compared to the empty vector group and normal group (P<0.01). There were a greater number of apoptotic cells in the pcDNA3.1-SASH1 group compared to the empty vector group and normal group (P<0.01). Taken together, these results indicated that SASH1 may be a tumor suppressor gene in ovarian carcinoma, and SASH1 expression inhibited growth, proliferation and migration, and enhanced apoptosis of SKOV3 cells.

show abstract

Distribution and case-fatality ratios by cell-type for ovarian carcinomas: A 22-year series of 562 patients with uniform current histological classification

Cited by 24 publications

References 38 publications

Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)

Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)

Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma

Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma

Contact Info

Product

Resources

About